Tamoxifen - Revision history

Lazy at 08:16, 18 January 2025

2025-01-18T08:16:59Z

← Older revision		Revision as of 01:16, 18 January 2025
Line 13:		Line 13:
	\|toxicity_level=3.5		\|toxicity_level=3.5
	\|toxicity_explanation=Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage.		\|toxicity_explanation=Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage.
	}}		\|overview=Tamoxifen, an FDA-approved drug for breast cancer, is currently under investigation in Phase II clinical trials and retrospective studies for its potential to treat glioblastoma (GBM) through protein kinase C inhibition. Early evidence suggests it may improve survival and progression-free outcomes in select GBM patients, though its use at high dosages carries notable side effects and toxicity risks.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:24:00Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:24, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups.		\|notes=While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=3.5		\|toxicity_level=3.5
	\|toxicity_explanation=Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage.		\|toxicity_explanation=Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage.
	}}		}}

Lazy at 16:52, 27 March 2024

2024-03-27T16:52:58Z

← Older revision		Revision as of 09:52, 27 March 2024
Line 11:		Line 11:
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
			\|toxicity_level=3.5
			\|toxicity_explanation=Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage.
	}}		}}

Lazy at 16:53, 19 March 2024

2024-03-19T16:53:22Z

← Older revision		Revision as of 09:53, 19 March 2024
Line 2:		Line 2:
	\|drug_name=Tamoxifen		\|drug_name=Tamoxifen
	\|FDA_approval=Yes (for breast cancer treatment)		\|FDA_approval=Yes (for breast cancer treatment)
	\|used_for=Investigational use in glioblastoma (GBM) ~~treatment~~		\|used_for=Investigational use in glioblastoma (GBM) due to its inhibition of protein kinase C
	\|clinical_trial_phase=Phase II clinical trials and retrospective studies		\|clinical_trial_phase=Phase II clinical trials and retrospective studies for GBM
	\|common_side_effects=~~Increased~~ risk of ~~blood clots,~~ uterine cancer in women, impotence, and loss of libido in men, weight gain		\|common_side_effects=Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain
	~~\|OS_without=Not specified~~		\|OS_with=Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics
	\|OS_with=~~Varies; in gliomas, doses range from 160-240 mg per day showed tumor regression in 25% of patients~~		\|PFS_with=In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens
	~~\|PFS_without=Median~~ survival ~~time~~ for ~~GBM typically ranges from 3-7 months~~ with ~~second-line chemotherapy~~
	\|PFS_with=~~Median~~ survival ~~of 16 months for Grade III tumors and 7.2 months~~ for GBM ~~with tamoxifen~~ treatment
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=~~Tamoxifen, a well-~~known breast cancer ~~therapy~~, ~~inhibits~~ protein kinase C ~~in gliomas~~, ~~potentially slowing~~ cancer ~~cell growth and stimulating angiogenesis at high doses. Early studies indicate its promise in tumor regression and survival extension~~, ~~with some patients experiencing major benefits. Its effectiveness and~~ side effects~~, especially at high doses required~~ for ~~glioma~~ treatment, ~~highlight the need for~~ further research to identify responsive patient groups ~~and optimize treatment protocols~~.		\|notes=While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups.
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Tamoxifen |FDA_approval=Yes (for breast cancer treatment) |used_for=Investigational use in glioblastoma (GBM) treatment |clinical_trial_phase=Phase II clinical trials and retrospective studies |common_side_effects=Increased risk of blood clots, uterine cancer in women, impotence, and loss of libido in men, weight gain |OS_without=Not specified |OS_with=Varies; in gliomas, doses range from 160-240 mg per day showed tumor regression in 25% of pat..."

2024-03-19T16:48:35Z

Created page with "{{TreatmentInfo |drug_name=Tamoxifen |FDA_approval=Yes (for breast cancer treatment) |used_for=Investigational use in glioblastoma (GBM) treatment |clinical_trial_phase=Phase II clinical trials and retrospective studies |common_side_effects=Increased risk of blood clots, uterine cancer in women, impotence, and loss of libido in men, weight gain |OS_without=Not specified |OS_with=Varies; in gliomas, doses range from 160-240 mg per day showed tumor regression in 25% of pat..."

New page

{{TreatmentInfo
|drug_name=Tamoxifen
|FDA_approval=Yes (for breast cancer treatment)
|used_for=Investigational use in glioblastoma (GBM) treatment
|clinical_trial_phase=Phase II clinical trials and retrospective studies
|common_side_effects=Increased risk of blood clots, uterine cancer in women, impotence, and loss of libido in men, weight gain
|OS_without=Not specified
|OS_with=Varies; in gliomas, doses range from 160-240 mg per day showed tumor regression in 25% of patients
|PFS_without=Median survival time for GBM typically ranges from 3-7 months with second-line chemotherapy
|PFS_with=Median survival of 16 months for Grade III tumors and 7.2 months for GBM with tamoxifen treatment
|usefulness_rating=3
|notes=Tamoxifen, a well-known breast cancer therapy, inhibits protein kinase C in gliomas, potentially slowing cancer cell growth and stimulating angiogenesis at high doses. Early studies indicate its promise in tumor regression and survival extension, with some patients experiencing major benefits. Its effectiveness and side effects, especially at high doses required for glioma treatment, highlight the need for further research to identify responsive patient groups and optimize treatment protocols.
|category=Repurposed Drugs
|links=
}}